Global Age-Related Macular Degeneration Market to Reach US$16.4 Billion by 2030

The global market for Age-Related Macular Degeneration estimated at US$10.9 Billion in the year 2024, is expected to reach US$16.4 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Eylea Age-related Macular Degeneration, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$7.9 Billion by the end of the analysis period. Growth in the Lucentis Age-related Macular Degeneration segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 11.2% CAGR

The Age-Related Macular Degeneration market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Age-Related Macular Degeneration Market - Key Trends & Drivers Summarized

Why Is the Prevalence of Age-Related Macular Degeneration Increasing Globally?

The rising global prevalence of age-related macular degeneration is driven by the rapidly aging population and increasing life expectancy. As the proportion of elderly individuals grows, the incidence of AMD, a leading cause of irreversible vision loss in older adults, continues to escalate. Lifestyle factors such as unhealthy diets, smoking, and prolonged exposure to blue light from digital screens have also contributed to the rising burden of AMD worldwide. Moreover, the growing awareness about eye health and the increasing frequency of routine eye examinations are leading to earlier diagnosis and treatment of AMD, thereby expanding the market for therapeutic interventions. Healthcare organizations and governments are intensifying efforts to educate the public about the importance of early detection and preventive measures, which is positively impacting the demand for AMD-related diagnostics and treatments.

How Are Advances in Treatment Options Shaping the AMD Market?

Innovative treatment approaches and the introduction of novel therapies are significantly transforming the AMD market landscape. Anti-vascular endothelial growth factor (anti-VEGF) injections continue to dominate the treatment paradigm for wet AMD, offering improved vision outcomes and slowing disease progression. However, recent advancements in gene therapy, stem cell research, and sustained drug delivery systems are offering new hope for patients with both wet and dry AMD. Emerging therapies, such as complement inhibitors and oral treatments targeting inflammation and oxidative stress, are gaining traction as potential disease-modifying solutions. Additionally, the development of longer-acting biologics and implantable drug delivery devices is improving patient compliance by reducing the frequency of injections. As pharmaceutical companies continue to invest heavily in R&D, the pipeline for AMD treatments remains robust, promising a shift towards more personalized and effective therapeutic options.

What Are the Key Market Challenges and Opportunities?

Despite the significant progress in AMD treatment, challenges such as high treatment costs, limited access to advanced therapies, and the absence of a definitive cure for dry AMD continue to pose hurdles to market growth. The high price of anti-VEGF injections, coupled with the need for frequent administration, places a financial burden on patients and healthcare systems, particularly in low- and middle-income countries. Additionally, the lack of effective therapies for geographic atrophy, an advanced form of dry AMD, remains an unmet need, driving researchers to explore novel therapeutic targets. However, these challenges present opportunities for innovation, with market players focusing on cost-effective solutions and patient-friendly drug delivery mechanisms. The increasing adoption of teleophthalmology and artificial intelligence-based screening tools is also opening new avenues for early detection and remote monitoring, enhancing accessibility and patient outcomes.

What Are the Key Factors Driving Growth in the AMD Market?

The growth in the Age-Related Macular Degeneration market is driven by several factors, including the rising aging population, increasing adoption of advanced treatment modalities, and the expanding availability of healthcare services globally. The growing focus on precision medicine and biomarker-driven therapies is leading to more targeted and effective treatments, further boosting market growth. Additionally, the increasing prevalence of lifestyle-related risk factors, such as diabetes and hypertension, which contribute to AMD progression, is fueling the demand for early interventions and preventive measures. The expansion of healthcare infrastructure, particularly in emerging economies, and the growing investment by pharmaceutical companies in ophthalmology research are also contributing to market growth. Furthermore, the introduction of reimbursement policies and patient assistance programs is making AMD treatments more accessible, driving higher treatment adoption rates across different demographics.